Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:03 2024-06-21 pm EDT 5-day change 1st Jan Change
148.8 USD +0.66% Intraday chart for Johnson & Johnson +2.21% -5.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Edge Up in Afternoon Trading MT
Johnson & Johnson: filing in Crohn's disease CF
Johnson & Johnson: acquisition of Proteologix completed CF
Johnson & Johnson Completes Acquisition of Proteologix MT
Johnson & Johnson Completes Acquisition of Proteologix MT
Johnson & Johnson Completes Acquisition of Proteologix MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million. CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease CI
J&J: launches open, secure digital ecosystem CF
J&J: promising results in Crohn's disease CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints MT
Johnson & Johnson Sees Positive Trial Results for Tremfya DJ
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease CI
J&J: FDA application in lung cancer CF
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer MT
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer CI
J&J: positive results in Sjögren's disease CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study CI
EU regulator mandates label updates on CAR-T cancer therapies RE
J&J: encouraging trial in relapsing multiple myeloma CF
J&J: the promise of ibrutinib in CLL CF
J&J: promising results for Imbruvica in leukemia CF
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
148.8 USD
Average target price
171.7 USD
Spread / Average Target
+15.44%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Johnson & Johnson to Buy Proteologix For $850 Million in Cash